Rapamycin and Longevity in Germany

Rapamycin (also called sirolimus) started as a drug pulled from a soil bacterium called Streptomyces hygroscopicus on Easter Island (Rapa Nui). The FDA approved it in 1999 as the immunosuppressant Rapamune (Wyeth-Ayerst, then Pfizer after Pfizer bought Wyeth in October 2009). The European Commission granted an EU-wide marketing authorisation on 13 March 2001. The original job: calm the immune system down after a kidney transplant.

How it works: Rapamycin blocks a protein complex called mTOR (a cellular switch that senses nutrients), and specifically the mTORC1 version. mTOR runs cell growth, protein building, and autophagy (the cell's way of cleaning out its own junk).

Why the longevity crowd cares: In animal studies, nothing has extended lifespan as reliably as rapamycin. Harrison 2009 (Nature, NIH Interventions Testing Program) reported median lifespan extension of +9% in male and +13% in female mice on encapsulated rapamycin started at 600 days of age. Independent rodent ITP and other-cohort replications, plus Drosophila (Bjedov 2010 Cell Metab) and C. elegans TOR/IIS work (Robida-Stubbs 2012 Cell Metab), broadly back the direction across species, even if the invertebrate effects are modest and strain-dependent.

One thing to be clear about: Rapamycin is not a longevity supplement. It is a prescription drug that really does suppress the immune system and bring other side effects, so any off-label use carries real risks.

This guide is not medical advice.

The mTOR longevity idea goes like this:

1. mTOR is an old nutrient-surplus sensor that flips on whenever real quantities of food are around. Lots of food keeps it switched on.
2. Keeping mTOR high for too long appears to speed up aging, because it shuts down autophagy and feeds zombie cells (old cells that refuse to die and drive chronic inflammation).
3. Anything that dials mTOR down extends animal lifespan, including eating less, fasting, and rapamycin.
4. Rapamycin is the most direct mTOR dial-down, because it works on a controllable dose schedule rather than a behaviour you have to keep up for life.

Mouse trials (NIH Intervention Testing Program):

• Rapamycin given to older mice extended median lifespan by ~9% (males) and ~13% (females), and 90th-percentile lifespan by ~9% (males) and ~14% (females), even when started late in life (Harrison et al., Nature, 2009). The often-quoted 14% female figure refers specifically to 90th-percentile (maximum) lifespan; the matching median is 13%.
• The effect held up across different mouse strains. That matters, because most rodent longevity findings fall apart the moment you change the genetic background.
• The bigger the dose, the bigger the effect.

The big open questions for people:

• Humans already age 30 to 50 times slower than mice, so a 15 percent bump on a 2-year mouse life does not automatically become 15 percent on 80 human years.
• Suppressing the immune system at age 70, with normal infections going around, is a real and ongoing concern even at weekly doses.
• Daily versus once a week dosing: newer protocols use low weekly doses to cut immune effects, but the evidence behind that schedule is still thin.

Human data on rapamycin for longevity is much thinner than the animal record. Most of what we have comes from short trials with surrogate endpoints, not mortality.

Direct longevity trials in people:

• PEARL study (AgelessRx/Lifespan.io, NCT04488601; published April 2025 in Aging (Albany NY); Matt Kaeberlein has commented on the trial externally but was not a formal advisor) ran a 48-week randomized placebo-controlled trial of rapamycin 5 mg and 10 mg weekly using compounded rapamycin, which has been reported to have lower bioavailability than brand-name Rapamune (a recognised study limitation), in healthy adults. The pre-registered primary endpoint was change in visceral adipose tissue on DEXA scan, and it was not met. Significant secondary improvements in lean tissue mass and self-reported pain scores showed up specifically in the female 10 mg arm.
• Lower-dose immune trials: Mannick et al. ran two related trials in older adults. The 2014 paper (Sci Transl Med) tested everolimus (RAD001) alone, with arms ranging from 0.5 mg daily up to 20 mg weekly. The 2018 paper (Sci Transl Med) tested RTB101 monotherapy and a low-dose RTB101 + everolimus 0.1 mg combination at different doses. In the 2018 study, only the RTB101 10 mg once-daily arm met the prespecified primary endpoint; higher-dose and RTB101+everolimus combination arms did not. A later phase 3 trial (Mannick et al., Lancet Healthy Longevity 2021) did not replicate the phase 2b benefit, which ended the RTB101 immune-boosting development programme. This is specific to RTB101, not to rapamycin itself.

What we see in transplant patients:

• People on rapamycin after a transplant develop less skin cancer, and possibly fewer of some other cancers, though the absolute numbers come from a population already immunosuppressed for other reasons.
• That does not translate cleanly to longevity use in otherwise healthy adults.

Most common side effects at longevity doses (5 to 6 mg per week):

• Mouth ulcers (the most frequent complaint; a topical dexamethasone mouthwash can help)
• Occasional signs of a weakened immune response, such as longer or more frequent minor infections
• Higher blood fats (triglycerides and LDL)
• Higher blood sugar
• Proteinuria, a kidney side effect classical in transplant use, rare at weekly longevity doses but still monitored via urine ACR
• Impaired wound healing. Pause rapamycin at least two weeks before any planned surgery and restart only after the wound is fully healed
• Pneumonitis or interstitial lung disease, uncommon but listed in the SmPC; a new dry cough or breathlessness warrants urgent evaluation
• Interactions with many drugs through the liver enzyme CYP3A4

Absolute contraindications and cautions:

• Pregnancy and breastfeeding. Rapamycin causes embryo-fetal toxicity in animal studies (fetal death and reduced fetal weight; no structural malformations were seen), and it can cause fetal harm based on those findings and its mechanism. Effective contraception is required on treatment and for 12 weeks after stopping.
• Live-attenuated vaccines (yellow fever, MMR, varicella, nasal influenza) are contraindicated while on rapamycin, so finish any needed travel vaccines before starting or during a planned pause.
• Recent or upcoming surgery: see the wound-healing note above.
• Active infection or unhealed wound: pause until it resolves.

What we still do not know:

• Long-term safety over 10 or more years in healthy adults
• The best dose and schedule
• Who actually benefits

Rapamycin (sirolimus) is approved as a medicine in Germany, but only for specific uses:

• Immune suppression after kidney transplant
• Lymphangioleiomyomatosis (LAM, a rare lung disease)
• Some vascular malformations (off-label)

Longevity is not an approved use. Any prescription written for that purpose counts as off-label. That is legally allowed, but it means the doctor carries more liability and has to counsel you more carefully than usual.

What that means in practice:

• Statutory health insurance only pays for rapamycin in approved uses, so for longevity you pay 100 percent yourself out of pocket.
• Cost: At Apothekenverkaufspreis (AVP), Rapamune 1 mg tablets run about €11.85 each (Lauer-Taxe / gelbe-liste.de spot-check, 2026; verify before publication). At 5 to 6 mg per week, that works out to roughly €240 to 310 per month. The lower €60 to 150/month range only applies when you source parallel imports or compounded sirolimus from compounding pharmacies.
• Getting a prescription: You need a doctor willing to prescribe off-label, and in Germany very few practices do. The US has online services for this; Germany does not.
• Advertising law (HWG): Advertising rapamycin with longevity claims is not allowed.

Importing from countries outside the EU/EEA (India, Turkey): mail-order of prescription medicines from non-EU/EEA countries to private individuals is prohibited under §73 Arzneimittelgesetz (AMG), and this is not a grey zone. German Customs (Zoll) routinely inspects international mail and seizes such parcels; recipients can face warnings, fines, and in some cases criminal investigation. A separate and narrow allowance lets a traveller personally carry up to a 3-month supply of a non-narcotic prescription drug in their luggage when entering Germany, but that does not cover postal orders. Even if a shipment slips through, there is no quality control. Not recommended.

For NMN and related grey-zone questions see the NMN Germany guide.

If you are seriously thinking about rapamycin for longevity, the only sensible path runs through a doctor who knows the drug and is willing to monitor you properly.

This guide does not give dosing advice. The eligibility criteria and lab thresholds below are items to discuss with the prescribing physician, not self-managed thresholds, because off-label rapamycin needs individual physician supervision and informed consent.

Start / don't-start signals:

• Probably NOT a candidate if you have recurrent infections, plan surgery in the next 6 months, have uncontrolled HbA1c (>6.5%), LDL-C >160 mg/dL, are immunocompromised, have active cancer under treatment, are pregnant, nursing, or planning pregnancy within 12 months, or are under 45 without a specific accelerated-ageing profile.
• Possibly a candidate if you are age 55+, metabolically healthy, with LDL-C and HbA1c in range, no planned surgeries, willing to pause dosing for any acute infection, have a prescribing physician available for quarterly monitoring, and understand that this is off-label and evidence-light.

Which doctor to approach:

• Internal medicine specialists with a preventive or longevity angle
• Longevity private practices in Munich, Berlin, Hamburg, Frankfurt
• Not your standard GP without specific training

Finding a prescriber in DACH: Very few German Hausärzte will prescribe rapamycin off-label, so the more realistic route is internal-medicine physicians with the Zusatzbezeichnung Naturheilverfahren or Ernährungsmedizin (the two formal BÄK Zusatz-Weiterbildungen relevant here; "Präventivmedizin" is a curricular Fortbildung, not a Zusatzbezeichnung), or dedicated longevity private practices in Munich, Berlin, Hamburg, Frankfurt, Vienna, Zurich. Useful search tools: arzt-auskunft.de with the relevant Zusatzbezeichnung filter, or the Ärztekammer Bayern/ÖÄK/FMH directories. Expect €200 to 500 for a first Selbstzahler visit.

CYP3A4 interactions to know (everyday hazards): do not combine rapamycin with grapefruit juice or grapefruit fruit (raises rapamycin levels), St. John's wort or rifampicin (both strong inducers that lower rapamycin levels, with rifampicin the textbook drop, relevant if you are on TB therapy or some staphylococcal prophylaxis), clarithromycin or erythromycin, ketoconazole or itraconazole, diltiazem or verapamil. Many statins need dose adjustment when taken alongside it, and you should always give your pharmacist and doctor a full medication list, including over-the-counter and herbal products.

Lab monitoring schedule if on off-label rapamycin:

• Baseline: CBC, metabolic panel (CMP), fasting lipids, HbA1c, fasting glucose, lipase, urine ACR, vitamin D, blood pressure, TB screening.
• Week 4: recheck CBC, CMP, fasting glucose, lipids, lipase.
• Quarterly ongoing: the same labs.
• Stop-thresholds: ANC <1.5, new proteinuria, triglycerides >500, HbA1c climbing >0.5% above baseline, persistent mouth ulcers despite dose adjustment, any active infection (pause until resolved).

Women's-health note: Rapamycin (sirolimus) was historically labelled FDA Pregnancy Category C because animal embryo-fetal toxicity has been shown (fetal death and reduced fetal weight, not structural malformations). The FDA dropped the A/B/C/D/X letter system in 2015 under the Pregnancy and Lactation Labeling Rule (PLLR), so the current Rapamune label uses a narrative 'Risk Summary' stating the drug can cause fetal harm based on animal data and mechanism of action. Effective contraception is required while on treatment and for 12 weeks after stopping. Not for use in nursing mothers. There is no longevity use-case that justifies rapamycin in pregnancy or breastfeeding.

Before you go, get clear on:

• Your current markers (blood panel, heart and blood vessel risk, metabolic profile)
• Any drugs you take that interact with rapamycin (the CYP3A4 list)
• Any current or chronic infections
• How much risk you are personally willing to take

Reasonable questions to ask:

1. Do you know the current longevity data on rapamycin?
2. Are you willing to prescribe off-label and document it properly?
3. Which lab values would you track?
4. How often should I come back for check-ins?
5. What would make you stop treatment?

A doctor who will not take these questions seriously is not the right partner. A doctor who will prescribe without any questions is not either.